Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Indivior PLC Ordinary Shares (INDV)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: INDV (5-star) is a STRONG-BUY. BUY since 28 days. Simulated Profits (23.62%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $37.86
1 Year Target Price $37.86
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 156.46% | Avg. Invested days 42 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.58B USD | Price to earnings Ratio 37.35 | 1Y Target Price 37.86 |
Price to earnings Ratio 37.35 | 1Y Target Price 37.86 | ||
Volume (30-day avg) 7 | Beta 1.11 | 52 Weeks Range 7.62 - 38.00 | Updated Date 12/9/2025 |
52 Weeks Range 7.62 - 38.00 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.51% | Operating Margin (TTM) 36.94% |
Management Effectiveness
Return on Assets (TTM) 13.06% | Return on Equity (TTM) 12.2% |
Valuation
Trailing PE 37.35 | Forward PE 12.3 | Enterprise Value 4301857981 | Price to Sales(TTM) 3.88 |
Enterprise Value 4301857981 | Price to Sales(TTM) 3.88 | ||
Enterprise Value to Revenue 3.65 | Enterprise Value to EBITDA 16.11 | Shares Outstanding 125024430 | Shares Floating 95138670 |
Shares Outstanding 125024430 | Shares Floating 95138670 | ||
Percent Insiders 3.87 | Percent Institutions 81.49 |
Upturn AI SWOT
Indivior PLC Ordinary Shares
Company Overview
History and Background
Indivior PLC was spun off from Reckitt Benckiser in December 2014. It inherited the opioid dependence treatment business, including Suboxone. Significant milestones include the launch of Sublocade and the ongoing legal challenges related to opioid addiction litigation. The company has undergone strategic shifts to diversify its product portfolio beyond its legacy opioid dependence treatments.
Core Business Areas
- Opioid Dependence Treatments: Development and commercialization of medications and long-acting injectable treatments for opioid use disorder (OUD), aiming to help individuals achieve long-term recovery. Key products include Suboxone (buprenorphine and naloxone) and Sublocade (buprenorphine extended-release injection).
- Behavioral Health and Addiction Treatments: Expanding into broader mental health and addiction treatment areas beyond OUD, including the development of novel therapies for conditions like schizophrenia and ADHD.
Leadership and Structure
Indivior PLC is a public limited company headquartered in Richmond, Virginia, USA, and London, UK. It is listed on the London Stock Exchange. The leadership team includes a CEO, CFO, and other executive officers responsible for various functions such as R&D, commercial operations, and corporate affairs. The company operates through various subsidiaries and has a global presence.
Top Products and Market Share
Key Offerings
- Product Name 1: [object Object]
- Product Name 2: [object Object]
- Product Name 3: [object Object]
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the addiction and mental health space, is characterized by significant R&D investment, complex regulatory pathways, and intense competition. The opioid crisis has driven increased focus and funding for addiction treatments. The market for long-acting injectables and novel non-opioid therapies is expanding.
Positioning
Indivior is a well-established player in the opioid use disorder treatment market, with a legacy of leading products. Its positioning is evolving from a focus on oral buprenorphine to a broader portfolio including long-acting injectables and potential expansion into other mental health areas. Its competitive advantage lies in its established expertise in addiction medicine, R&D pipeline, and relationships within the treatment community.
Total Addressable Market (TAM)
The global market for addiction and mental health treatments is substantial and growing, estimated to be in the tens of billions of dollars. Indivior's Total Addressable Market for its current and pipeline products is a significant portion of this, particularly within OUD and expanding into broader behavioral health. Indivior is positioned to capture a meaningful share through its specialized products and therapies.
Upturn SWOT Analysis
Strengths
- Strong brand recognition and established market presence in OUD treatment.
- Expertise in the development and commercialization of addiction therapies.
- Pipeline of novel treatments, including long-acting injectables and non-opioid options.
- Established global distribution and sales network.
Weaknesses
- Dependence on a few key products, with ongoing generic competition impacting revenue.
- Significant legal and financial exposure related to opioid litigation.
- Need for diversification beyond the core OUD market.
- High R&D costs and the inherent risks associated with drug development.
Opportunities
- Expanding into other areas of mental health and addiction beyond OUD.
- Growth in the long-acting injectable market for addiction treatments.
- Partnerships and collaborations to accelerate pipeline development and market access.
- Increased global awareness and funding for addiction treatment.
Threats
- Continued generic competition for existing products.
- Adverse outcomes from ongoing opioid litigation.
- Regulatory hurdles and challenges in drug approval processes.
- Emergence of new and more effective competing therapies.
- Shifts in healthcare policy and reimbursement landscapes.
Competitors and Market Share
Key Competitors
- Emergent BioSolutions Inc. (USA: EBS)
- Alkermes Plc (USA: ALKS)
- Mallinckrodt Pharmaceuticals (USA: MNK - Note: Currently in Chapter 11 restructuring)
Competitive Landscape
Indivior competes in a complex and evolving market. Its advantages lie in its specialized focus and established expertise in addiction. However, it faces competition from larger pharmaceutical companies with broader portfolios and from other specialized biotechs. The litigation environment also presents a unique challenge that competitors do not universally face to the same degree.
Growth Trajectory and Initiatives
Historical Growth: Indivior experienced significant growth driven by the success of Suboxone in its early years. However, this growth has been challenged by the advent of generic competition and ongoing litigation.
Future Projections: Future growth is projected to be driven by the successful commercialization of Sublocade, the development and launch of new pipeline assets (e.g., Persys), and potential expansion into new therapeutic areas. Analyst estimates suggest a gradual recovery and growth as the company diversifies its revenue streams.
Recent Initiatives: Recent initiatives include the ongoing build-out of the Sublocade franchise, the advancement of its pipeline, strategic partnerships, and ongoing efforts to manage its legal exposures and optimize its cost structure.
Summary
Indivior PLC faces a critical juncture. While its legacy in opioid dependence treatments provides a strong foundation, the company is navigating significant headwinds from generic competition and substantial opioid litigation. Its future strength hinges on the successful expansion of its long-acting injectable franchise (Sublocade), the development and commercialization of its pipeline assets like Persys, and its ability to diversify beyond its core OUD market. Careful management of legal liabilities and strategic investments in R&D will be crucial for its long-term viability and growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Indivior PLC Investor Relations
- Financial news outlets (e.g., Bloomberg, Reuters)
- Pharmaceutical industry analysis reports
- SEC filings
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share information can be dynamic and subject to change. Users should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indivior PLC Ordinary Shares
Exchange NASDAQ | Headquaters North Chesterfield, VA, United States | ||
IPO Launch date 2014-12-29 | CEO & Director Mr. Joseph J. Ciaffoni | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1030 | Website https://www.indivior.com |
Full time employees 1030 | Website https://www.indivior.com | ||
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.